<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">59831</article-id><article-id pub-id-type="doi">10.7554/eLife.59831</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Evolved bacterial resistance against fluoropyrimidines can lower chemotherapy impact in the <italic>Caenorhabditis elegans</italic> host</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-198372"><name><surname>Rosener</surname><given-names>Brittany</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198393"><name><surname>Sayin</surname><given-names>Serkan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198374"><name><surname>Oluoch</surname><given-names>Peter O</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7451-4993</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198375"><name><surname>García González</surname><given-names>Aurian P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-198376"><name><surname>Mori</surname><given-names>Hirotada</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-13890"><name><surname>Walhout</surname><given-names>Albertha JM</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5587-3608</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-182640"><name><surname>Mitchell</surname><given-names>Amir</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9376-3987</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Program in Systems Biology</institution>, <institution>University of Massachusetts Medical School</institution>, <addr-line><named-content content-type="city">Worcester</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Graduate School of Biological Sciences</institution>, <institution>Nara Institute of Science and Technology</institution>, <addr-line><named-content content-type="city">Ikoma</named-content></addr-line>, <country>Japan</country></aff><aff id="aff3"><institution content-type="dept">Program in Systems Biology, Program in Molecular Medicine, Department of Molecular, Cell and Cancer Biology</institution>, <institution>University of Massachusetts Medical School</institution>, <addr-line><named-content content-type="city">Worcester</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-61468"><name><surname>Landry</surname><given-names>Christian R</given-names></name><role>Reviewing editor</role><aff><institution>Université Laval</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>amir.mitchell@umassmed.edu</email> (AM);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>11</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e59831</elocation-id><history><date date-type="received"><day>09</day><month>06</month><year>2020</year></date><date date-type="accepted"><day>25</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Rosener et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Rosener et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-59831-v1.pdf"/><abstract><p>Metabolism of host-targeted drugs by the microbiome can substantially impact host treatment success. However, since many host-targeted drugs inadvertently hamper microbiome growth, repeated drug administration can lead to microbiome evolutionary adaptation. We tested if evolved bacterial resistance against host-targeted drugs alters their drug metabolism and impacts host treatment success. We used a model system of <italic>C. elegans</italic>, its bacterial diet, and two fluoropyrimidine chemotherapies. Genetic screens revealed that most of loss-of-function resistance mutations in <italic>Escherichia coli</italic> also reduced drug toxicity in the host. We found that resistance rapidly emerged in <italic>E. coli</italic> under natural selection and converged to a handful of resistance mechanisms. Surprisingly, we discovered that nutrient availability during bacterial evolution dictated the dietary effect on the host – only bacteria evolving in nutrient-poor media reduced host drug toxicity. Our work suggests that bacteria can rapidly adapt to host-targeted drugs and by doing so may also impact the host.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>C. elegans</italic></kwd><kwd><italic>E. coli</italic></kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>NIGMS</institution></institution-wrap></funding-source><award-id>R35GM133775</award-id><principal-award-recipient><name><surname>Mitchell</surname><given-names>Amir</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>NIGMS</institution></institution-wrap></funding-source><award-id>DK068429</award-id><principal-award-recipient><name><surname>Walhout</surname><given-names>Albertha JM</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>NIGMS</institution></institution-wrap></funding-source><award-id>GM122393</award-id><principal-award-recipient><name><surname>García González</surname><given-names>Aurian P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Sequencing data was deposited in SRA under the BioProjects IDs PRJNA645604 and PRJNA645605</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Timothy A Scott</collab></person-group><year iso-8601-date="2017">2017</year><source>Table S2</source><ext-link ext-link-type="uri" xlink:href="DOI:https://doi.org/10.1016/j.cell.2017.03.040">DOI:https://doi.org/10.1016/j.cell.2017.03.040</ext-link><comment>Supplementary information, mmc2.xlsx</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-59831-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>